List of Excipients in Branded Drug TIZANIDINE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Actavis Pharma Inc	TIZANIDINE HYDROCHLORIDE	tizanidine hydrochloride	0591-2788	FD&C BLUE NO. 1
Actavis Pharma Inc	TIZANIDINE HYDROCHLORIDE	tizanidine hydrochloride	0591-2788	GELATIN
Actavis Pharma Inc	TIZANIDINE HYDROCHLORIDE	tizanidine hydrochloride	0591-2788	HYPROMELLOSES
Actavis Pharma Inc	TIZANIDINE HYDROCHLORIDE	tizanidine hydrochloride	0591-2788	SILICON DIOXIDE
Actavis Pharma Inc	TIZANIDINE HYDROCHLORIDE	tizanidine hydrochloride	0591-2788	SUCROSE

Generic Drugs Containing TIZANIDINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Eon Labs Inc	tizanidine hydrochloride	0185-0034	CELLULOSE, MICROCRYSTALLINE
Eon Labs Inc	tizanidine hydrochloride	0185-0034	LACTOSE MONOHYDRATE
Eon Labs Inc	tizanidine hydrochloride	0185-0034	SILICON DIOXIDE
Eon Labs Inc	tizanidine hydrochloride	0185-0034	STEARIC ACID
Rebel Distributors	tizanidine hydrochloride	21695-126	ANHYDROUS LACTOSE

What are the Most Frequently-Used Excipients in TIZANIDINE HYDROCHLORIDE?

# Of NDCs	Excipient
18	ALCOHOL
20	AMMONIA
17	ANHYDROUS LACTOSE
18	BUTYL ALCOHOL
25	CELLULOSE, MICROCRYSTALLINE

Excipient Strategy and Commercial Opportunities for Tizanidine Hydrochloride

Last updated: February 25, 2026

What is the Role of Excipient Strategy in Tizanidine Hydrochloride Formulations?

Excipient selection influences stability, bioavailability, manufacturability, and patient compliance of Tizanidine Hydrochloride. A well-designed excipient profile can enhance drug performance, extend shelf life, and reduce manufacturing costs.

What Are the Current Formulation Types for Tizanidine Hydrochloride?

Tizanidine Hydrochloride is available in various formulations:

• Oral tablets (standard and extended-release)
• Oral capsules

The majority of formulations use excipients that facilitate rapid dissolution and absorption.

Which Excipients Are Common in Tizanidine Hydrochloride Formulations?

• Binders: Microcrystalline cellulose, povidone
• Disintegrants: Croscarmellose sodium, sodium starch glycolate
• Lubricants: Magnesium stearate, stearic acid
• Fillers/Diluents: Lactose monohydrate, dibasic calcium phosphate
• Coatings: Hydroxypropyl methylcellulose (HPMC), cellulose derivatives

Extended-release formulations deploy polymer matrices like ethylcellulose or polyethylene oxide to control drug release.

How Does Excipient Choice Affect Manufacturing and Stability?

Excipients influence:

• Manufacturing: Flowability, compressibility, and processability of powders.
• Stability: Moisture-sensitive excipients like lactose require protective packaging.
• Drug release profile: Osmotic, matrix, or coating systems depend on excipient properties.

Optimizing excipient composition improves batch consistency and shelf stability, essential for commercial success.

What Are the Commercial Opportunities in Excipient Innovation?

Market Trends and Growth Drivers

• Growing demand for extended-release formulations increases the need for advanced excipients like controlled-release polymers.
• Favorable regulatory environment for excipient modifications that enhance bioavailability.
• Rise in generic Tizanidine Hydrochloride formulations prompts innovation in cost-effective excipient blends.

Opportunities

• Development of excipients that enable smaller tablet sizes improves patient adherence.
• Use of natural or plant-based excipients meets consumer preferences and regulatory shifts.
• Incorporation of multifunctional excipients reduces formulation complexity and costs.

Patent Landscape and Competition

• Few patents restrict excipient use specific to Tizanidine formulations, creating room for innovation.
• Companies patent novel excipient combinations that tailor drug release or improve stability, protecting market share.

What Are the Regulatory Considerations?

• Excipients must meet pharmacopeial standards (USP, EP).
• Newly developed excipients or formulations need clearance via FDA or EMA.
• Regulatory agencies assess excipient safety, compatibility, and impact on bioequivalence.

How Can Pharmaceutical Companies Leverage Excipient Strategies?

• Invest in R&D for excipients that enhance bioavailability, especially for reformulations.
• Collaborate with excipient manufacturers developing innovative, patentable materials.
• Focus on formulations that improve patient compliance, such as smaller or less frequent dosing tablets.

Summary of Key Commercial Opportunities

Opportunity Area	Specific Focus	Potential Benefit
Extended-release formulations	Use of controlled-release polymers	Market share, premium pricing
Excipient innovation	Natural, multifunctional, or multifunction polymer excipients	Cost reduction, consumer appeal
Reformulation for bioavailability	Improving solubility with excipient modifications	New patent filings, competitive advantage
Size reduction and compliance	Excipient systems enabling smaller tablets	Patient adherence, marketability

Key Takeaways

• Excipient selection impacts formulation performance, stability, and manufacturability of Tizanidine Hydrochloride.
• Market growth driven by demand for extended-release and patient-friendly formulations.
• Innovation in excipients, including natural and multifunctional types, offers avenues for differentiation.
• Regulatory compliance and safety are critical in excipient development.
• Strategic collaborations with excipient suppliers can accelerate product development and protect market position.

FAQs

1. What excipients are critical in Tizanidine Hydrochloride extended-release formulations?
Polymer matrices such as ethylcellulose, polyethylene oxide, and hydroxypropyl methylcellulose are used to control drug release.

2. How does excipient choice influence bioavailability?
Excipients can enhance solubility, protect the drug from degradation, and modulate release profiles, all affecting bioavailability.

3. Are there regulatory barriers to novel excipients in Tizanidine formulations?
Yes. New excipients require regulatory approval, which involves demonstrating safety and compatibility.

4. What trends are shaping excipient development in the Tizanidine market?
Preferring natural, plant-based, and multifunctional excipients for improved patient acceptance and manufacturing efficiency.

5. How significant is patenting in excipient innovation for Tizanidine?
Patent protection for excipient combinations or delivery systems can create competitive barriers and unlock licensing revenues.

References

1. U.S. Pharmacopeia. (2022). Excipient monographs.
2. European Pharmacopoeia. (2022). Excipients standards.
3. Wilkes, L., & McKnight, D. (2020). Innovations in pharmaceutical excipients. International Journal of Pharmaceutics, 586, 119595.
4. EMA. (2022). Guidance on excipient safety assessment.
5. FDA. (2021). Guidance for Industry: Testing of excipients for pharmaceutical formulations.